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Abstract
Background: YKL-40 is a chitinase-like glycoprotein encoded by the chitinase 3-like 1 gene, CHI3L1, localized at
chromosome 1q32.1. Increased levels of serum YKL-40 have been reported to be a biomarker for asthma and a reduced lung
function. Interestingly, the C-allele of the -131 CRG (rs4950928) polymorphism of CHI3L1 has been shown to associate with
bronchial hyperresponsiveness and reduced lung function suggesting that variations in CHI3L1 may influence risk of asthma.
The objective of the present study was to investigate the association of common variation in the CHI3L1 locus with asthma,
atopy and lung function in a large population-based sample of adults.
Methods/Principal Findings: Eleven single nucleotide polymorphisms (SNPs) of CHI3L1 including rs4950928 were
genotyped in 6514 individuals. Asthma was defined as self-reported history of physician-diagnosed asthma. Total IgE and
specific IgE to inhalant allergens were measured on serum samples. Lung function was measured by spirometry.
Homozygosity of the rs4950928 G allele as compared to homozygosity of the C allele was associated with self-reported
physician diagnosed asthma (OR 1.5 (95% CI, 1.00–2.26)) and with prevalence of atopic asthma (OR 1.93 (95% CI, 1.21–3.07))
after adjustment for age, sex, smoking status, socio-economic class and BMI. Carriers of rs883125 G allele had a significantly
lower prevalence of atopy (OR 0.82 (CI, 0.72; 0.94)) as compared to homozygosity of the C allele. None of the SNPs examined
were significantly associated with FEV1. However, two SNPs (rs10399931and rs4950930) appeared to be significantly
associated with FEV1/FVC-ratio. Subgroup analyses of never-smokers did not consistently influence the associations in an
either positively og negatively way.
Conclusions: In contrast to previous studies, the rs4950928 G allele, and not the C allele, was found to be associated with
asthma. A few other SNPs of the CHI3L1 was found to be significantly associated with atopy and FEV1/FVC ratio,
respectively. Thus, more studies seem warranted to establish the role of CHI3L1 gene in asthma and atopy.
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Introduction
YKL-40 is a chitinase-like glycoprotein encoded by the chitinase
3-like 1 gene, CHI3L1, localized at chromosome 1q32.1. YKL-40
belongs to the evolutionary conserved family of 18-glycosyl
hydrolases, which consists of enzymatic active chitiniases as well
as chitinase-like proteins without enzymatic properties. Chitinases
function as effector molecules and mediate airway inflammation in
both human epithelial cells [1] and in mouse models of asthma
[2,3]; however, despite the lack of enzymatic properties, YKL-40
levels are elevated in serum and in the lungs of patients with
asthma where they correlate positively with the severity of the
disease and inversely with lung function [4] indicating a
participation of YKL-40 in the activity level and/or the
pathogenesis of the disease.
A study investigating various polymorphisms of CHI3L1 in
relation to sarcoidosis has found that the CHI3L1 -329 G/A
polymorphism (rs10399931) contributes to interindividual varia-
tions of YKL-40 levels in patients with sarcoidosis but does not
influence sarcoidosis susceptibility or disease severity [5]. In a
genome wide association study CHI3L1 was found to be a
susceptibility gene for asthma, bronchial hyperresponsiveness and
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YKL-40 level was a biomarker for asthma and reduced lung
function [6]. In relation to asthma, the causal SNP was -131 CRG
(rs4950928) in the core promoter region of CHI3L1. Recently, the
-247C/T promoter polymorphism (rs10399805) of CHI3L1 was
found to associate with serum YKL-40 levels and the risk of atopy
in children [7].
The objective of the present study was to investigate the putative
association of common variation in the CHI3L1 locus with asthma,
atopy and asthma quantitative traits including measures of lung
function in a large sample of adults Danes.
Methods
Ethics Statement
Informed written consent was obtained from all participants
before participation. The study was approved by the Ethical
Committees of Copenhagen and Aarhus and was in accordance
with the principle of the Helsinki Declaration II.
Study population
The current study is based on the baseline examination of
participants in the Inter99 study, a population-based randomized
controlled trial, investigating the effect of lifestyle intervention
(smoking cessation, increased physical activity, and healthier
dietary habits) on CVD [8]. The present study was focused on
the baseline data before any intervention had been offered. Data
were collected with self-administered questionnaires, a physical
examination, and blood tests. Details on the study population,
health examination, and the intervention program have been
described elsewhere [8]. Briefly, the Inter99 study population were
residents in the southern part of the former Copenhagen County.
An age- and sex-stratified random sample of 13,016 men and
women born in 1939–40, 1944–45, 1949–50, 1954–55, 1959–60,
1964–65, and 1969–70 was drawn from the Civil Registration
System and invited to participate in a health examination during
1999–2001, so that they were aged 30, 35, 40, 45, 50, 55, 60, and
65 years on the day of the examination. A total of 12,934 were
eligible for invitation. The baseline participation rate was 52.5%
(n=6,784). Only participants with a Northern European nation-
ality were included in the current study (n=6,514).
Measurement of serum total IgE, serum specific IgE to
aeroallergens and lung function
Measurement of specific IgE in serum is the gold standard for
assessment of respiratory allergy in large-scale epidemiological
studies. Serum samples collected at baseline were analysed for
serum total IgE as well as serum specific IgE against four inhalant
allergens (birch, grass, cat, and house dust mite (Dermatophagoi-
des pteronyssinus)) by using the ImmuliteH 2000 Allergy
Immunoassay System [9,10]. The four allergens chosen reflects
the most common and clinical important inhalant allergies in
Denmark. A positive test to at least one of these four allergens will
identify up to 90% of individuals skin prick test positive to at least
one inhalant allergen in a standard panel of 10 inhalant allergens
in the background population studied. Atopy was defined as a
positive test for specific IgE ($0.35 kU/L) to at least one of the
four allergens.
Spirometry was performed by using the CardiosoftH software
(GE Medical Systems, Freiburg, Germany) and LF501 respiration
flow transducer (Erich Jaeger B.V. and Marquette Hellige GmbH,
Freiburg, Germany). Predicted values of FEV1 and FVC were
calculated [11]. Measured values of FEV1 and FVC were
expressed as per cent of predicted.
Definition of asthma and atopic asthma
Self-reported physician-diagnosed asthma was defined as a
confirmative answer to the question ‘‘Has a physician ever told you that
you have asthma?’’
Atopic asthma was defined as self-reported physician-diagnosed
asthma combined with atopy (specific IgE positivity to aeroaller-
gens).
Information on potential confounders
Smoking was recorded as: never smokers, ex-smokers, occa-
sional smokers (,1 gram tobacco per day) and daily smokers. A
history of chronic disease (yes/no) was defined as a positive answer
to questions regarding physician diagnosed diabetes, hypertension,
cerebrovascular disease, ischemic heart disease and other cardiac
diseases. Social class was defined on the basis of questions
regarding number of years of vocational training and employment
status and categorised into five classes: class 1 (unemployed and no
vocational training), class 2 (unemployed and .1 year of
vocational training), class 3 (employed and no vocational training),
class 4 (employed and 1–3 years of vocational training), class 5
(employed and .3 years of vocational training). Height and
weight were measured wearing light clothes and no shoes. Body
mass index (BMI) was calculated as weight divided by height
squared. BMI were categorized according to the following criteria
recommended by WHO: underweight (,18.5 kg/m
2), normal
range ($18.5–25 kg/m
2), overweight ($25–30 kg/m
2) and obese
($30 kg/m
2) [12].
Genotyping of single nucleotide polymorphisms in the
CHI3L1 gene
A region 22 kb upstream and 10 kb downstream of CHI3L1
were chosen from the HapMap project (www.hapmap.org) and
HapMap Data Rel 21a/phaseII Jan07, on NCBI assembly,
dbSNP b125, were used for the SNP selection. A total of 11
tgSNPs (including rs10399931 and rs4950928) located 14 kb
upstreams and 2 kb downstreams and covering all LD blocks in
CHI3L1 were genotyped. TAGGER chose these SNPs as the most
informative in that +20 kb–210 kb region.
TAGGER was used with a 5% MAF cut off and aggressive
tagging, i.e. r
2.0.8. Genotyping was performed using Taqman
allelic discrimination (Kbioscience, Herts, UK) with a success rate
.97.0%. Discordance was 0% as judged from re-genotyping of
965 random duplicate samples. Genotype distribution obeyed
Hardy Weinberg Equilibrium (HWE), all p.0.25.
Statistical analyses
Statistics were computed with the statistical program SAS,
version 9.1 (SAS Institute Inc, Cary, NC, USA). All p-values
reported are two-tailed and statistical significance was defined as
p,0.05. All association analyses were done in the subgroup of
never-smokers as well as in the total study population to see
whether smoking amplified possible associations of SNPs in
CHI3L1 with asthma, atopy or asthma quantitative traits. The
associations between SNPs in CHI3L and the dichotomous
outcomes were examined by logistic regression. Results are
reported as odds ratios (ORs) with 95% confidence intervals
(95% CI). Differences were tested by the likelihood ratio test.
The association between CHI3L1 SNPs and the continous
outcomes were examined in linear regression models. Serum total
IgE levels were log-transformed to achieve a normal distribution.
Results are reported as b coefficients with 95% CI, except for
serum total IgE levels where inverse transformations of model
estimates were performed to provide proportional differences in %
CHI3L1 and Asthma/Atopy
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models were adjusted for sex, age, smoking status (in the analyses
of the total study population), BMI and social status. Age and BMI
were tested for linear associations with the outcomes by including
the squared terms of the variables in the respective models. In case
of a non-linear relationship the variable was either categorized or
the squared term of the variable was included in the model. Test
for linear trends across genotype groups was performed by
including the genotype groups as continuous variables in the
regression models. P-values are not adjusted for multiple testing.
Results
Clinical characteristics of the Inter99 cohort are presented in
Table 1. A total of 2319 (35.9%) individuals were daily smokers.
Atopy was diagnosed in 1994 (32.3%) individuals and physician-
diagnosed was reported from 540 (8.6%) individuals. Atopic
asthma was present in 300 (4.8%) individuals. In the subgroup of
never-smokers (2202 (34.0%)), atopy was diagnosed in 781 (36.4%)
individuals and physician-diagnosed was reported from 210 (9.5%)
individulas. Atopic asthma was present in 145 (6.6%).
The prevalences of the 11 tgSNPs of CHI3L1 are shown in
Table S1. All SNPs presented MAFs.5% except from rs4950930
(MAF=4.5%).
Homozygosity of the rs4950928 G allele (MAF=20.5%) as
compared to homozygosity of the C allele was significantly
associated with the prevalence of atopic asthma (OR 1.93 (95%
CI, 1.21; 3.07) and with self-reported physician diagnosed asthma
(OR 1.50 (95% CI, 1.00; 2.26) after adjustment for age, sex,
smoking status, socio-economic class and BMI) (Table 2). In never-
smokers similar adjusted association between homozygosity of the
rs4950928 G allele and atopic asthma was seen (OR 2.17 (95% CI,
1.10; 4.29) (Table S2).
On the other hand CG heterozygothy of rs4950928 had a small
protective effect against atopic asthma (OR 0.60 (95% CI; 0.39;
0.93) and physician diagnosed asthma (OR 0.64 (95% CI, 0.5;
0.91) among never-smokers when compared with CC homozy-
gosity (Table S2).
In the total population but not in the subgroup of never-
smokers, carriers of the G allele of rs883125 were protected
against the prevalence of atopy (OR 0.82 (CI, 0.72; 0.94)) as
compared to homozygosity of the C allele (Table 2).
In the total population homozygothy of the rs2486064 A allele
was positively associated with shortness of breath when at rest (OR
1.33 (95% CI, 1.06; 1.68), p=0.05) whereas homozygosity of the
minor A allele of rs2886117 were protective against shortness of
breath when at rest (OR 0.43 (95% CI, 0.18; 0.98), p=0.02)(data
not shown). Among never-smokers homozygosity of the rs2886117
A allele was found to be protective against atopy (OR 0.34 (95%
CI, 0.13; 0.90) (Supplementary data, Table B). Neither rs2886117
nor rs2486064 were associated with any other clinical information
of asthmatic symptoms, with the presence of atopic asthma or with
measures of lung function neither in the total population nor
among never-smokers (Table 2–3 and Table S2–S3).
In multivariate adjusted analyses none of the SNPs were
significantly associated with FEV1 neither in the total population
nor among never-smokers. In the total study population, both
rs10399931 and rs4950930 were associated with FEV1/FVC-ratio
(forced expiratory volume in the first second/forced expiratory
vital capacity) (Table 3). Homozygosity of the minor T allele of
rs10399931 had a positive effect on FEV1/FVC-ratio (b=1.1
(95% CI, 0.2; 2.0)), whereas homozygosity of the minor A allele of
rs4950930 had a negative effect on FEV1/FVC-ratio (b=24.2
(95% CI, 28.0; 20.4)). Similar associations were not seen among
never-smokers where homozygosity of the rs661378 A allele
however was found to be associated with a lower FEV1/FVC ratio
(b=3.8 (95% CI, 0.9; 6.8) (Table S3). None of the remaining
investigated variations of CHI3L1 were significantly associated
with asthma, atopy or asthma-related traits or with measures of
lung function (Table 3). None of the SNPs were associated with
serum total IgE (data not shown).
A combined analysis (Mantel-Haenszel test) for asthma with our
rs4950928 data and previously published rs4950928 data [6,7] was
performed. However, the three studies were significantly different
and OR could not be combined in a meta-analysis (p=0.01).
Discussion
This is the first large-scale study of variation in CHI3L1 in
relation to asthma and atopy in a population-based sample of
adults. CHI3L1 encodes the inflammatory protein YKL-40 and
circulating levels of this protein are reported to be elevated in
patients with respiratory inflammatory diseases such as asthma
[4,6] and sarcoidosis [5,13]. In patients with asthma, but not in
patients with sarcoidosis, serum YKL-40 levels also seems to be a
biomarker of severity of the disease [4]. Different genome wide
association studies have shown, that SNPs in the CHI3L1
promoter are associated with differential gene expression [14],
transcript levels [15] and circulating YKL-40 levels [5,14].
Recently, variation in the CHI3L1 promoter was also found to
associate with atopy [7].
We examined 6514 adult Danes of which 8.6% had physician
diagnosed asthma, 4.8% suffered from atopic asthma and 32.3%
were diagnosed with atopy. Similiar prevalences were found in the
subgroup of never-smokers. In the total population we found an
Table 1. Clinical characteristics of the study population.
Sex (males) 48.7 (3,169/6,514)
a
Age 46.20 (30.63–61.72)
b
Daily smokers 35.9 (2,319/6,467)
a
Never-smokers 34.0 (2,202/6,467)
a
BMI 26.3 (17.2–35.4)
b
Highest social class ($4 years education,
employed){
38.0 (2,282/6,002)
a
Chronic disease{{ 22.2 (1,446/6,514)
a
‘‘Has a physician ever told you that you have
asthma?’’
8.6 (540/6,287)
a
Atopy{{{ 32.3 (1,994/6,172)
a
Atopic asthma 4.8 (300/6,270)
a
Serum total IgE (kU/L) 29.85 (1.70–525.12)
b
Percent of predicted FEV1 97.0 (68.8–125.2)
b
Percent of predicted FVC 103.0 (75.2–130.9)
b
FEV1/FVC in percent 78.8 (63.3–94.3)
b
a% (n/ntotal).
bgeometric mean (95% prediction interval).
BMI, body mass index.
{Social class were defined in 5 categories based on employment status and
years of education.
{{A history of chronic disease was defined as a positive answer to questions
regarding physician diagnosed diabetes, hypertension, cerebrovascular
disease, ischemic heart disease, and other cardiac diseases.
{{{Atopy was defined as a positive test for specific IgE to at least one of four
common inhalant allergens.
doi:10.1371/journal.pone.0006106.t001
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a of atopy, atopic asthma and self-reported physician diagnosed
asthma according to single nucleotide polymorphisms (SNPs) of CHI3L1.
SNP
Allele
(major/minor) Genotype
‘‘Have a physician ever told you
you had asthma?’’ Atopic asthma{ Atopy{
Prevalence OR (95% CI)
c Prevalence OR (95% CI)
c Prevalence OR (95% CI)
c
rs883125 C/G CC 8.52 (366/4297)
a 1.00 5.01 (215/4291)
a 1.00 33.43 (1438/4302)
a 1.00
CG 9.07 (142/1565) 1.00 (0.80; 1.24) 4.66 (73/1565) 0.89 (0.67; 1.19) 29.86 (464/1554) 0.82 (0.72; 0.74)
GG 6.62 (10/151) 0.69 (0.33;1.42) 3.97 (6/151) 0.60 (0.22;1.64) 29.93 (44/147) 0.86 (0.59; 1.26)
p=0.54
b p=0.56 p=0.75
b p=0.44 p=0.03
b p=0.01
rs880633 C/T CC 9.12 (162/1776) 1.00 4.85 (86/1773) 1.00 33.11 (587/1773) 1.00
CT 8.15 (239/2934) 0.96 (0.77;1.20) 4.81 (141/2931) 1.03 (0.77; 1.38) 31.82 (933/2932) 0.95 (0.83; 1.09)
TT 8.33 (105/1260) 1.00 (0.76;1.32) 4.84 (61/1260) 1.03 (0.72; 1.47) 32.51 (410/1261) 0.99 (0.84; 1.16)
p=0.50 p=0.91 p=1.00 p=0.98 p=0.65 p=0.73
rs4950928 C/G CC 8.94 (343/3838) 1.00 5.16 (198/3834) 1.00 31.84 (1218/3825) 1.00
CG 7.40 (144/1947) 0.86 (0.69;1.06) 3.91 (76/1944) 0.76 (0.57; 1.01) 32.92 (643/1953) 1.07 (0.94; 1.20)
GG 11.63 (30/258) 1.50 (1.00;2.26) 8.53 (22/258) 1.93 (1.21; 3.07) 36.72 (94/256) 1.28 (0.97; 1.68)
p=0.03 p=0.04 p,0.01 p,0.01 p=0.23 p=0.17
rs10399931 C/T CC 9.03 (317/3509) 1.00 5.22 (183/3506) 1.00 32.19 (1125/3495) 1.00
CT 7.61 (162/1968) 0.87 (0.71;1.07) 4.14 (88/2128) 0.80 (0.61; 1.05) 32.41 (693/2138) 1.02 (0.90; 1.15)
TT 10.43 (36/345) 1.30 (0.98;1.90) 6.67 (23/345) 1.39 (0.87; 2.21) 33.53 (115/343) 1.07 (0.84; 1.37)
p=0.08 p=0.12 p=0.06 p=0.07 p=0.88 p=0.84
rs6691378 G/A GG 8.67 (404/4662) 1.00 4.83 (225/4655) 1.00 32.70 (1525/4663) 1.00
GA 8.12 (103/1268) 0.90 (0.71;1.15) 5.04 (64/1269) 0.96 (0.71; 1.31) 31.99 (404/1263) 0.96 (0.83; 1.10)
AA 10.34 (9/87) 1.25 (0.59;2.64) 4.60 (4/87) 1.10 (0.39; 3.04) 30.59 (26/85) 0.86 (0.52; 1.43)
p=0.70 p=0.57 p=0.95 p=0.96 p=0.83 p=0.70
rs4950930 G/A GG 8.38 (462/5513) 1.00 4.74 (261/5506) 1.00 32.31 (1778/5503) 1.00
GA 10.17 (49/482) 1.21 (0.86;1.69) 6.21 (30/483) 1.30 (0.86; 1.98) 33.81 (164/485) 1.05 (0.85; 1.29)
AA 7.14 (1/14) 0.74 (0.10;5.76) 7.14 (1/14) 1.34 (0.17; 10.40) 28.57 (4/14) 0.76 (0.24, 2.47)
p=0.33 p=0.54 p=0.24 p=0.48 p=0.79 p=0.82
rs12123883 T/C TT 8.46 (439/5191) 1.00 4.76 (247/5191) 1.00 32.53 (1690/5195) 1.00
TC 9.17 (74/807) 1.14 (0.86;1.49) 5.36 (43/802) 1.18 (0.83; 1.67) 30.95 (247/798) 0.92 (0.46; 1.85)
CC 5.26 (2/38) 0.61 (0.14;2.57) 2.63 (1/38) 0.60 (0.08; 4.42) 33.33 (13.39) 0.92 (0.77; 1.09)
p=0.68 p=0.50 p=0.70 p=0.55 p=0.67 p=0.59
rs2486064 G/A GG 8.52 (174/2042) 1.00 4.84 (99/2044) 1.00 32.36 (655/2024) 1.00
GA 8.39 (242/2885) 1.01 (0.81; 1.25) 4.65 (134/2883) 0.95 (0.72; 1.26) 32.05 (932/2908) 0.91 (0.85; 1.10)
AA 9.37 (102/1089) 1.23 (0.94;1.61) 5.82 (63/1083) 1.31 (0.93; 1.84) 33.74 (363/1076) 1.07 (0.91; 1.27)
p=0.61 p=0.25 p=0.31 p=0.15 p=0.60 p=0.42
rs2886117 G/A GG 8.64 (399/4619) 1.00 4.81 (222/6119) 1.00 32.42 (1498/4620) 1.00
GA 8.32 (110/1322) 0.92 (0.73;1.17) 5.14 (68/1324) 1.00 (0.74; 1.34) 32.50 (428/1317) 1.00 (0.87; 1.14)
AA 8.41 (9/107) 0.97 (0.46;2.03) 4.67 (5/107) 1.11 (0.44; 2.76) 28.57 (30/105) 0.80 (0.51; 1.27)
p=0.93 p=0.80 p=0.89 p=0.98 p=0.70 p=0.64
rs872129 A/G AA 8.65 (442/5109) 1.00 4.94 (252/5103) 1.00 32.70 (1663/5086) 1.00
AG 8.47 (74/874) 0.90 (0.68;1.19) 4.58 (40/874) 0.81 (0.55; 1.18) 30.47 (270/886) 0.87 (0.74; 1.03)
GG 9.52 (4/42) 1.44 (0.50;4.13) 7.14 (3/42) 1.71 (0.52; 5.65) 35.71 (15/42) 1.05 (0.53; 2.08)
p=0.90 p=0.59 p=0.59 p=0.37 p=0.90 p=0.27
rs871799 G/C GG 8.58 (420/4896) 1.00 4.89 (239/4892) 1.00 32.46 (1583/4877) 1.00
GC 8.47 (90/1062) 0.88 (0.68;1.14) 4.91 (52/1060) 0.84 (0.60; 1.18) 32.06 (345/1076) 0.94 (0.81; 1.09)
CC 4.23 (3/71) 0.32 (0.08;1.33) 1.41 (1/71) 0.27 (0.04; 1.96) 36.23 (25/69) 1.04 (0.62; 1.75)
p=0.43 p=0.12 p=0.47 p=0.17 p=0.77 p=0.68
{Atopy was defined as a positive test for specific IgE to at least one of four common inhalant allergens.
{Atopic asthma was defined as atopy in combination with self-reported physician-diagnosed asthma.
a%( n / n total). All such values. Ntotal may differ due to missing data.
bp values of chi square test/Fisher’s exact test.
cOR (95% CI) were estimated in logistic regression models. Models were adjusted for sex, age, bmi, smoking status, and social class.
doi:10.1371/journal.pone.0006106.t002
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SNP
Allele
(major/minor) Genotype Percent of predicted FEV1 Percent of predicted FVC FEV1/FVC in percent
Mean Effect Mean Effect Mean Effect
rs883125 C/G CC 96.9 (96.5; 97.3) 0.0 103.2 (102.7; 103.6) 0.0 78.7 (78.4; 78.9) 0.0
CG 97.6 (96.8; 98.3) 0.7 (20.1; 1.5) 103.1 (102.4; 103.8) 0.1 (20.8; 0.9) 79.2 (78.8; 79.6) 0.5 (0.1; 1.0)
GG 96.6 (94.3;98.9) 0.7 (21.6; 3.0) 102.2 (99.8; 104.5) 0.2 (22.1; 2.4) 78.7 (77.5; 80.0) 0.4 (20.9; 1.7)
p=0.29;
ptrend=0.28
p=0.21;
ptrend=0.09
p=0.70;
ptrend=0.56
p=0.99;
ptrend=0.87
p=0.08;
ptrend=0.06
p=0.07;
ptrend=0.04
rs880633 C/T CC 97.0 (96.4; 97.7) 0.0 103.5 (102.8; 104.1) 0.0 78.6 (78.2; 79.0) 0.0
CT 97.1 (96.6; 97.7) 0.0 (20.8; 0.8) 103.1 (102.6; 103.6) 20.3 (21.2; 0.5) 78.9 (78.6; 79.2) 0.3 (20.2; 0.7)
TT 97.0 (96.2; 97.8) 20.2 (21.2; 0.9) 102.7 (101.9; 103.5) 20.7 (21.7; 0.3) 79.0 (78.5; 79.4) 0.4 (20.2; 1.0)
p=0.94;
ptrend=0.99
p=0.93;
ptrend=0.77
p=0.38;
ptrend=0.16
p=0.40;
ptrend=0.17
p=0.42;
ptrend=0.21
p=0.36;
ptrend=0.16
rs4950928 C/G CC 97.1 (96.6; 97.5) 0.0 103.3 (102.9; 103.8) 0.0 78.7 (78.4; 78.9) 0.0
CG 97.2 (96.6; 97.9) 0.1 (20.7; 0.9) 103.0 (102.3; 103.6) 20.3 (21.0; 0.5) 79.0 (78.6; 79.3) 0.3 (20.1; 0.7)
GG 96.8 (94.9; 96.6) 20.7 (22.6; 1.1) 101.7 (99.9; 103.5) 21.8 (23.6; 0.0) 79.6 (78.6; 80.7) 0.8 (20.2; 1.8)
p=0.88;
ptrend=0.92
p=0.69;
ptrend=0.75
p=0.18;
ptrend=0.10
p=0.14;
ptrend=0.10
p=0.11;
ptrend=0.04
p=0.15;
ptrend=0.05
rs10399931 C/T CC 97.2 (96.7; 97.7) 0.0 103.5 (103.0; 104.0) 0.0 78.7 (78.4; 78.9) 0.0
CT 96.9 (96.3; 97.5) 20.2 (21.0; 0.6) 102.8 (102.1; 103.4) 20.5 (21.2; 0.3) 78.9 (78.6; 79.3) 0.2 (20.2; 0.7)
TT 97.5 (95.8; 99.3) 0.0 (21.6; 1.6) 102.0 (100.4; 103.7) 21.6 (23.1; 0.0) 79.9 (79.0; 80.7) 1.1 (0.2; 2.0)
p=0.68;
ptrend=0.84
p=0.87;
ptrend=0.74
p=0.06;
ptrend=0.02
p=0.11;
ptrend=0.04
p=0.03;
ptrend=0.01
p=0.04;
ptrend=0.02
rs6691378 G/A GG 97.2 (96.7; 97.6) 0.0 103.2 (102.8; 103.6) 0.0 78.9 (78.7; 79.1) 0.0
GA 96.8 (96.0; 97.6) 20.4 (21.3; 0.5) 102.9 (102.1; 103.7) 20.2 (21.0; 0.7) 78.6 (78.1; 79.1) 20.2 (20.7; 0.3)
AA 96.5 (93.4; 99.6) 21.1 (24.2; 2.0) 102.1 (99.1; 105.1) 21.3 (24.4; 1.8) 79.1 (77.0; 81.1) 0.0 (21.7; 1.8)
p=0.68;
ptrend=0.38
p=0.52;
ptrend=0.26
p=0.70;
ptrend=0.45
p=0.68;
ptrend=0.49
p=0.53;
ptrend=0.40
p=0.69;
ptrend=0.47
rs4950930 G/A GG 97.1 (96.7; 97.5) 0.0 103.1 (102.7; 103.5) 0.0 78.9 (78.7; 79.1) 0.0
GA 96.9 (95.7; 98.2) 20.3 (21.6; 1.1) 103.6 (102.4; 104.8) 0.5 (20.8; 1.8) 78.1 (77.4; 78.8) 20.7 (20.4; 0.1)
AA 92.6 (82.6; 102.7) 25.0 (211.8; 1.8) 102.5 (94.1; 10.8) 20.7 (27.4; 6.1) 76.0 (71.1; 81.0) 24.2 (28.0; 20.4)
p=0.46;
ptrend=0.48
p=0.33;
ptrend=0.38
p=0.73;
ptrend=0.50
p=0.73;
ptrend=0.52
p=0.05;
ptrend=0.02
p=0.02;
ptrend=0.02
rs12123883 T/C TT 97.0 (96.6;97.4) 0.0 103.0 (102.6, 103.4) 0.0 78.8 (78.6; 79.1) 0.0
TC 97.5 (96.5; 98.5) 0.50 (20.6; 1.6) 103.8 (102.8; 104.7) 1.0 (20.1; 2.0) 78.7 (78.1; 79.3) 20.4 (21.0; 0.2)
CC 95.5 (90.1; 101.0) 0.50 (24.0; 5.0) 100.4 (95.1; 105.7) 20.9 (25.4; 3.5) 79.8 (77.0; 82.5) 1.3 (21.3; 3.8)
p=0.59;
ptrend=0.63
p=0.64;
ptrend=0.36
p=0.20;
ptrend=0.41
p=0.17;
ptrend=0.14
p=0.69trend=0.89 p=0.24trend=0.42
rs2486064 G/A GG 96.8 (96.2; 97.4) 0.0 102.8 (102.2; 103.4) 0.0 78.8 (78.5; 79.2) 0.0
GA 97.4 (96.8; 97.9) 0.4 (20.4; 1.2) 103.5 (102.9; 104.0) 0.6 (20.2; 1.4) 78.8 (78.5; 79.1) 20.2 (20.6; 0.3
AA 96.8 (96.9; 97.7) 0.0 (21.1; 1.0) 102.8 (102.0; 103.6) 0.0 (21.0; 1.0) 79.0 (78.5; 79.5) 0.0 (20.6; 0.6)
p=0.32;
ptrend=0.70
p=0.61;
ptrend=0.84
p=0.22;
ptrend=0.71
p=0.24;
ptrend=0.72
p=0.76trend=0.67 p=0.65trend=0.93
rs2886117 G/A GG 97.2 (96.8; 97.6) 0.0 103.2 (102.8; 103.6) 0.0 78.9 (77.1; 80.5) 0.0
GA 96.8 (96.9; 97.6) 20.4 (21.3; 0.4) 103.0 (102.2; 103.8) 20.2 (21.1; 0.7) 78.6 (78.1; 79.0) 20.2 (20.7; 0.3)
AA 96.0 (93.2; 98.7) 21.2 (24.0; 1.6) 102.0 (99.2; 104.7) 21.0 (23.7; 1.8) 78.8 (77.1; 80.5) 20.2 (21.8; 1.3)
p=0.52;
ptrend=0.27
p=0.44;
ptrend=0.21
p=0.64;
ptrend=0.42
p=0.73;
ptrend=0.45
p=0.47;
ptrend=0.28
p=0.65;
ptrend=0.37
rs872129 A/G AA 97.1 (96.7; 97.5) 0.0 103.2 (102.8; 103.6) 0.0 78.8 (78.6; 79.0) 0.0
AG 96.8 (95.9; 97.8) 20.3 (21.3; 0.8) 102.7 (101.8; 103.6) 0.0 (20.9; 1.0) 79.0 (78.5; 79.5) 0.1 (20.5; 0.7)
GG 98.1 (93.2; 103.1) 1.0 (23.5; 5.5) 102.4 (98.0; 106.9) 1.0 (21.1; 3.1) 81.0 (78.7; 83.3) 1.5 (21.0; 4.1)
p=0.78;
ptrend=0.75
p=0.80;
ptrend=0.78
p=0.65;
ptrend=0.36
p=0.68;
ptrend=0.39
p=0.17;
ptrend=0.17
p=0.48;
ptrend=0.46
rs871799 G/C GG 97.0 (96.6; 97.4) 0.0 103.1 (102.7; 103.5) 0.0 78.8 (78.6; 79.0) 0.0
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allele (minor allele) of CHI3L1 and self-reported physician
diagnosed asthma. This is in contradiction with a previous study
of different populations by Ober et al [6]. Ober et al examined 4
different populations using the same diagnostic criterias and found
an association between rs4950928 and asthma in 3 of 4
populations due to a higher prevalence of the C and not the G
allele [6]. These 3 populations differed in many ways; one
population consisted of 753 genetically related individuals [16] of
which 63 suffered from asthma, another population consisted of
344 children with asthma (The Freiburg population) and the third
population consisted of a mix of 99 children and adults with
asthma recruited from an asthma clinic (Chicago population) [6].
Since the frequency of the G allele in our study is similar with
MAF in these populations, the discrepancy between the two
studies does not seem to arise from genotyping opposite strands.
Smoking could be an influencing factor on this association, since
we did not find similar association in the subgroup of never-
smokers. However, among never-smokers we did not find any
association between the rs4950928 C allele and asthma either. It
has previously been shown, that rs4950928 also accounts for 9.4%
of the variance in serum YKL-40 levels with the G allele having an
additive negative effect on serum YKL-40 levels [6].
We also found homozygosity of the rs4950928 G allele to be
positively associated with atopic asthma (defined as as a positive
test for specific IgE to at least one of four common inhalant
allergens combined with self-reported physician-diagnosed asth-
ma) with the highest OR among never-smokers indicating that
smoking does not enhance the OR. However, we found that
rs4950928 CG heterozygosity was protective against physician
diagnosed asthma and atopic asthma in the subgroup of never-
smokers but not in the total population indicating that smoking
obliterates this protective association. On the other hand, we also
found that rs 883125 CG heterozygosity was associated with a
significantly lower prevalence of atopy in the total population but
not in the subgroup of never-smokers.
We did not find an association between rs4950928 and total
serum IgE levels, which is in accordance with previous studies
where rs4950928 was not associated with total serum IgE or atopy
in any of the examined populations [6]. In a recent study of 295
Korean children with atopy, the rs10399805 CHI3L1 promoter
variant was associated with increased risk of atopy whereas an
association between rs4950928 and atopy was not seen and in
general no association between variations of CHI3L1 and asthma
was found [7].
Overall, we did not find convincing evidence that variations in
CHI3L1 have a strong influence on lung function, e.g. as reflected
by predicted FEV1. Among never-smokers AA homozygosity of
rs6691378 was associated with a higher FEV1/FVC-ratio which
was not seen in the total population. However, two SNPs
(rs10399931 and rs4950930) were associated with FEV1/FVC-
ratio in the total population but not in the subgroup of never-
smokers. In the present study, rs10399931 has a positive effect on
FEV1/FVC-ratio which is in contrast with a previous study of
patients with sarcoidosis [5]. Sarcoidosis patients have higher
serum YKL-40 levels compared to healthy controls, and in
sarcoidosis patients serum YKL-40 levels are correlated with
carbon monoxide diffusing lung capacity (DLCO) but not with
neither FEV1 nor FVC. However, only in the healthy controls,
rs10399931 contributes to the interindividual variations of serum
YKL-40 levels, and rs10399931 does not seem to influence
sarcoidosis susceptibility or severity [5]. On the other hand, the
negative effect of rs4950930 on FEV1/FVC-ratio has never been
shown previously.
CHI3L1 is located in an evolutionary conserved area of
chromosome 1q32.1, and YKL-40 belongs to the family of 18-
glycosyl hydrolases, which consists of chitinases as well as
chitinase-like proteins. Chitinases have been shown to mediate
airway inflammation [2] but even though YKL-40 lacks enzymatic
properties, serum YKL-40 concentrations have been shown to be
elevated in several acute and chronic inflammatory conditions
including asthma [4,6,17]. YKL-40 is also known to participate in
extracellular tissue remodelling and tissue fibrosis by increasing
fibroblast cell proliferation [17], and several studies have shown,
that YKL-40 plays a role in conditions leading to tissue fibrosis
[17–20]. This is in accordance with the finding, that serum YKL-
40 levels are elevated in patients with sarcoidosis, where it is
expressed by macrophages both in the pulmonary sarcoid
granulomas and in areas with inflammation [13]. A recent study
shows, that YKL-40 is upregulated in patients with chronic
obstructive pulmonary disease (COPD)[21], where it seems to
contribute to tissue inflammation and remodelling by activating
alveolar macrophages and sustaining their synthesis of proin-
flammatory and fibrogenic chemokines and metalloproteinases
[21]. We did not find any associations between the examined
SNPs of CHI3L1 and IgE levels, but a recent study in mice shows,
that YKL-40 is induced during the pathogenesis of aero-allergen-
induced Th2 inflammation and Il-13 effector responses and plays
a critical role in allergen sensitization, IgE induction, Th2 cytokine
production and macrophage activation [22]. All together, it seems
that genetic variations in CHI3L1 could account for inter-
individual YKL-40 levels and that YKL-40 in asthma, sarcoidosis
and COPD and plays a part of the pathogenesis with a role of
acute inflammatory as well as chronic fibrotic character. A linkage
disequilibrium (LD) plot of the examined variations of CHI3L1
shows, that the two functional promoter SNPs of CHI3L1,
Table 3. Cont.
SNP
Allele
(major/minor) Genotype Percent of predicted FEV1 Percent of predicted FVC FEV1/FVC in percent
Mean Effect Mean Effect Mean Effect
GC 97.4 (96.5; 98.3) 0.5 (20.5; 1.4) 103.3 (102.4; 104.1) 0.3 (20.6; 1.3) 78.9 (78.4; 79.4) 0.1 (20.4; 0.6)
CC 95.7 (92.1; 99.4) 21.0 (24.4; 2.4) 101.6 (98.0; 105.2) 20.8 (24.2; 2.6) 79.2 (77.2; 81.1) 20.2 (22.1; 1.7)
p=0.57;
ptrend=0.77
p=0.51;
ptrend=0.56
p=0.65;
ptrend=0.91
p=0.70;
ptrend=0.70
p=0.85;
ptrend=0.58
p=0.92;
ptrend=0.83
Differences were estimated in linear regression models adjusted for sex, age, bmi, smoking status, and social class.
FEV1, forced expiratory volume in the first second; FVC, forced expiratory vital capacity.
doi:10.1371/journal.pone.0006106.t003
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2=0.80) (Figure 1).
Pairwise these SNPs could account for a part of the role of CHI3L1
in asthma; however the nominally associations of the individual
SNPs does not add up to genotypes that are associated with both
clinical informations and symptoms of asthma and/or atopy as
well as measures of lung function.
In contrast to previous studies of variations in CHI3L1 in
relation to asthma, limitations of the present study are the lack of
measurements of serum YKL-40. However, the criterias for the
asthma diagnosis used in the present study are similar to the ones
used in previous studies on the effects of variation in CHI3L1 on
asthma. The advantage of the present study is the size of the study
population which adds statistical power and credibility to the
outcome of the analyses. However, the associations are not
corrected for multiple testing and some of the associations could be
chance findings. Furthermore, the significant differences in
prevalences of e.g. atopic asthma and effects on e.g. the
FEV1FVC-ratio are rather small and probably without any
clinical significance. Our results do not show, that smoking
consistently influence the associations in an either positively og
negatively way indicating that subgroup analyses correcting for
smoking status compromise the statistical power of the analyses
more than it strengthen the outcomes.
The meta-analysis of rs4950928 in asthma including our present
study and the previous studies by Ober et al [6] and Sohn et al [7],
showed significant heterogeneity and the three different studies
could not be combined. This may be caused by the rather small
sample sizes, and thus rather large confidence intervals from these
studies, in the two previous studies showing association with
asthma.
In conclusion, the present large population-based study
investigated the associations of variations of CHI3L1 with asthma
and atopy in unrelated adults. Both in the total population and
among never-smokers, The G allele of rs4950928 was associated
with atopic asthma which is contradictory to previous findings.
The rs4950928 G allele was also associated with self-reported
physician diagnosed asthma in the total population. Among never-
smokers rs4050928 CG heterozygosity was protective against
atopic asthma and self-reported physcian-diagnosed asthma.
Furthermore, in the total population carriers of the rs883125 G
allele were found to be protected against atopy whereas
homozygosity of the rs2886117 A allele was found to be protective
against atopy among never-smokers. None of the SNPs were
associated with FEV1, but two showed significant associations with
the FEV1/FVC-ratio. Overall, the study does not consistently
present specific variations of CHI3L1 that are associated with both
clinical informations and symptoms of asthma and/or atopy as
well as measures of lung function but the study does not exclude a
potential role of CHI3L1 in susceptibility to asthma. Smoking does
not consistently influence the associations in an either positively og
negatively way. None of the significant associations in this report
will resist corrections for multiple testing and obviously our
findings are by nature explorative and they should be tested in
independent study samples.
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Figure 1. Linkage disequilibrium (LD) plot of the investigated variations of CHI3L1. Numbers represents the r
2-values of the respective
SNPs. The bolded fonts are representative of SNPs that are informative in the respective LD-block.
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